1.Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S: Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018, 6(13):589–599.
2.Popping S, El-Sayed M, Feld J, Hatzakis A, Hellard M, Lesi O, Ninburg M, Ward J, Boucher C: Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17–18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. J Virus Erad 2018, 4(3):193–195.
3.Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, Kim HS, Lu SN, Sung J, Tanaka J et al: Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia. J Hepatol 2013, 59(5):1073–1080.
4.Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, Kelly DA: Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2019, 70(3):371–378.
5.Hajarizadeh B, Grebely J, Dore GJ: Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013, 10(9):553–562.
6.Disease GBD, Injury I, Prevalence C: Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390(10100):1211–1259.
7.Lanini S, Pisapia R, Capobianchi MR, Ippolito G: Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018, 16(8):625–639.
8.Lu J, Xu A, Wang J, Zhang L, Song L, Li R, Zhang S, Zhuang G, Lu M: Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 2013, 13:37.
9.Xiao J, Lin H, Liu T, Zeng W, Li X, Shao X, Tan Q, Xu Y, Xu X, Zheng H et al: Disease Burden from Hepatitis B Virus Infection in Guangdong Province, China. Int J Environ Res Public Health 2015, 12(11):14055–14067.
10.Collaborators GBDCoD: Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390(10100):1151–1210.
11.Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N et al: Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 2015, 3(11):e712–723.
12.Mortality GBD, Causes of Death C: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388(10053):1459–1544.
13.Organization WH. Geneva: Global Hepatitis Report, 2017. http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence = 1. Accessed Janurary 30 2019.
14.Xiaochang L, Ting Z, Zhimei Z, Jingdong W, Jiawei L, Wen Y, Jingsi Y: Incidence and trends of viral hepatitis in China. Prev Med (in Chineses) 2018, 30(5):433–437.
15.Wang FS, Fan JG, Zhang Z, Gao B, Wang HY: The global burden of liver disease: the major impact of China. Hepatology 2014, 60(6):2099–2108.
16.Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y et al: Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27(47):6550–6557.
17.WHO: WHO position paper on hepatitis A vaccines - June 2012. Wkly Epidemiol Rec 2012, 87(28/29):261–276.
18.Aggarwal R, Goel A: Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis 2015, 28(5):488–496.
19.Linder KA, Malani PN: Hepatitis A. JAMA 2017, 318(23):2393.
20.Polaris Observatory HCVC: Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017, 2(3):161–176.
21.Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K: Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol 2018, 24(24):2555–2566.
22.Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, Kelly DA: Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2018.
23.Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17(2):107–115.
24.Liu Z, Yang Q, Shi O, Ye W, Chen X, Zhang T: The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: An observational population-based study. J Viral Hepat 2018, 25(12):1543–1554.
25.Ogholikhan S, Schwarz KB: Hepatitis Vaccines. Vaccines (Basel) 2016, 4(1).
26.Man John Law L, Landi A, Magee WC, Lorne Tyrrell D, Houghton M: Progress towards a hepatitis C virus vaccine. Emerg Microbes Infect 2013, 2(11):e79.
27.Xue J, Zhu H, Chen Z: Therapeutic vaccines against hepatitis C virus. Infect Genet Evol 2014, 22:120–129.
28.Cruz HM, Barbosa JR, Baima Colares JK, de Moraes Neto AHA, Alencar MFL, Bastos FI, da Mota JC, Carvalho-Costa FA, Ivantes CAP, Lewis-Ximenez LL et al: Cross-sectional study to determine viral hepatitis knowledge in different urban populations in Brazil. World J Hepatol 2018, 10(11):867–876.
29.Hutin Y, Low-Beer D, Bergeri I, Hess S, Garcia-Calleja JM, Hayashi C, Mozalevskis A, Rinder Stengaard A, Sabin K, Harmanci H et al: Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers. JMIR Public Health Surveill 2017, 3(4):e91.
30.Cui F, Li L, Hadler SC, Wang F, Zheng H, Chen Y, Gong X, Hutin YJ, Cairns KL, Liang X et al: Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–2005. Vaccine 2010, 28(37):5973–5978.
31.Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, Zaer-rezaii H, Amini-Kafiabad S, Maghsudlu M, Pourshams A et al: Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 2010, 14 Suppl 3:e113–116.
32.Boulos D, Goedhuis NJ, Wu J, Baptiste B, Poliquin D, Furseth J, Chan JI, Bolesnikov G, Barichello F, Andonov A et al: Enhanced surveillance for acute and likely acute hepatitis B in Canada: 1999 to 2002. Can J Infect Dis Med Microbiol 2005, 16(5):275–281.
33.Shimelis T, Torben W, Medhin G, Tebeje M, Andualm A, Demessie F, Mulu A, Tegbaru B, Gebre-Selassie S: Hepatitis B virus infection among people attending the voluntary counselling and testing centre and anti-retroviral therapy clinic of St Paul’s General Specialised Hospital, Addis Ababa, Ethiopia. Sex Transm Infect 2008, 84(1):37–41.
34.DALYs GBD, Collaborators H: Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390(10100):1260–1344.